• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

计算预测靶向人类抗 V3 HIV 单克隆抗体的中和表位。

Computational prediction of neutralization epitopes targeted by human anti-V3 HIV monoclonal antibodies.

机构信息

Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, New York, United States of America.

Public Health Research Institute Center, Rutgers New Jersey Medical School, Newark, New Jersey, United States of America.

出版信息

PLoS One. 2014 Feb 25;9(2):e89987. doi: 10.1371/journal.pone.0089987. eCollection 2014.

DOI:10.1371/journal.pone.0089987
PMID:24587168
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3934971/
Abstract

The extreme diversity of HIV-1 strains presents a formidable challenge for HIV-1 vaccine design. Although antibodies (Abs) can neutralize HIV-1 and potentially protect against infection, antibodies that target the immunogenic viral surface protein gp120 have widely variable and poorly predictable cross-strain reactivity. Here, we developed a novel computational approach, the Method of Dynamic Epitopes, for identification of neutralization epitopes targeted by anti-HIV-1 monoclonal antibodies (mAbs). Our data demonstrate that this approach, based purely on calculated energetics and 3D structural information, accurately predicts the presence of neutralization epitopes targeted by V3-specific mAbs 2219 and 447-52D in any HIV-1 strain. The method was used to calculate the range of conservation of these specific epitopes across all circulating HIV-1 viruses. Accurately identifying an Ab-targeted neutralization epitope in a virus by computational means enables easy prediction of the breadth of reactivity of specific mAbs across the diversity of thousands of different circulating HIV-1 variants and facilitates rational design and selection of immunogens mimicking specific mAb-targeted epitopes in a multivalent HIV-1 vaccine. The defined epitopes can also be used for the purpose of epitope-specific analyses of breakthrough sequences recorded in vaccine clinical trials. Thus, our study is a prototype for a valuable tool for rational HIV-1 vaccine design.

摘要

HIV-1 毒株的极度多样性对 HIV-1 疫苗设计构成了巨大挑战。尽管抗体 (Abs) 可以中和 HIV-1 并可能预防感染,但针对免疫原性病毒表面蛋白 gp120 的抗体具有广泛的变异性和较差的预测交叉株反应性。在这里,我们开发了一种新的计算方法,即动态表位方法,用于鉴定抗 HIV-1 单克隆抗体 (mAbs) 靶向的中和表位。我们的数据表明,这种完全基于计算能量和 3D 结构信息的方法可以准确预测 V3 特异性 mAbs 2219 和 447-52D 靶向的中和表位在任何 HIV-1 株中的存在。该方法用于计算这些特定表位在所有循环 HIV-1 病毒中的保守范围。通过计算手段准确识别病毒中 Ab 靶向的中和表位,可以轻松预测特定 mAb 在数千种不同循环 HIV-1 变体中的反应广度,并有助于合理设计和选择模拟多价 HIV-1 疫苗中特定 mAb 靶向表位的免疫原。定义的表位还可用于对疫苗临床试验中记录的突破性序列进行表位特异性分析。因此,我们的研究是用于合理 HIV-1 疫苗设计的有价值工具的原型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d950/3934971/a459ea2af172/pone.0089987.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d950/3934971/1e6e6405eef7/pone.0089987.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d950/3934971/a459ea2af172/pone.0089987.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d950/3934971/1e6e6405eef7/pone.0089987.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d950/3934971/a459ea2af172/pone.0089987.g002.jpg

相似文献

1
Computational prediction of neutralization epitopes targeted by human anti-V3 HIV monoclonal antibodies.计算预测靶向人类抗 V3 HIV 单克隆抗体的中和表位。
PLoS One. 2014 Feb 25;9(2):e89987. doi: 10.1371/journal.pone.0089987. eCollection 2014.
2
Quantitative assessment of masking of neutralization epitopes in HIV-1.HIV-1 中和表位掩蔽的定量评估。
Vaccine. 2011 Sep 9;29(39):6736-41. doi: 10.1016/j.vaccine.2010.12.052. Epub 2011 Jan 7.
3
Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL.具有抗HIV-1 JRFL中和活性的人V3特异性单克隆抗体2424的功能与结构特征
J Virol. 2015 Sep;89(17):9090-102. doi: 10.1128/JVI.01280-15. Epub 2015 Jun 24.
4
Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies.人类抗V3单克隆抗体识别的1型人类免疫缺陷病毒表位的全球分布情况。
AIDS Res Hum Retroviruses. 2009 Apr;25(4):441-50. doi: 10.1089/aid.2008.0188.
5
Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.兔抗 HIV-1 gp120 第三可变环(V3)区抗体结构揭示抗原表位复杂度增加与抗体亲和力成熟及新结合模式的相关性。
J Virol. 2018 Mar 14;92(7). doi: 10.1128/JVI.01894-17. Print 2018 Apr 1.
6
Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes.针对HIV-1 gp120可变环表位的交叉亚型疫苗。
Vaccine. 2014 Sep 3;32(39):4916-24. doi: 10.1016/j.vaccine.2014.07.026. Epub 2014 Jul 18.
7
Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope.不同的机制调节HIV-1包膜V2和V3环中中和表位的暴露。
J Virol. 2014 Nov;88(21):12853-65. doi: 10.1128/JVI.02125-14. Epub 2014 Aug 27.
8
Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.能够呈现HIV-1 V3环冠部且构象适合产生447-52D样抗体的免疫原的设计。
Biochem J. 2006 Nov 1;399(3):483-91. doi: 10.1042/BJ20060588.
9
The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.一种人源单克隆抗体的跨亚型中和活性由1型人类免疫缺陷病毒的GPGR V3基序决定。
AIDS Res Hum Retroviruses. 2004 Nov;20(11):1254-8. doi: 10.1089/aid.2004.20.1254.
10
Indirect detection of an epitope-specific response to HIV-1 gp120 immunization in human subjects.在人体中对 HIV-1 gp120 免疫的表位特异性反应的间接检测。
PLoS One. 2011;6(11):e27279. doi: 10.1371/journal.pone.0027279. Epub 2011 Nov 4.

引用本文的文献

1
Convergent Evolution of Neutralizing Antibodies to Staphylococcus aureus γ-Hemolysin C That Recognize an Immunodominant Primary Sequence-Dependent B-Cell Epitope.中和抗体对金黄色葡萄球菌γ-溶血素 C 的趋同进化,该抗体可识别一个免疫显性的、依赖于初级序列的 B 细胞表位。
mBio. 2020 Jun 16;11(3):e00460-20. doi: 10.1128/mBio.00460-20.
2
Unbiased Identification of Immunogenic Staphylococcus aureus Leukotoxin B-Cell Epitopes.无偏鉴定免疫原性金黄色葡萄球菌白细胞毒素 B 细胞表位。
Infect Immun. 2020 Mar 23;88(4). doi: 10.1128/IAI.00785-19.
3
Weighted lambda superstrings applied to vaccine design.

本文引用的文献

1
Crystal structure of a soluble cleaved HIV-1 envelope trimer.可溶性 HIV-1 包膜三聚体的晶体结构
Science. 2013 Dec 20;342(6165):1477-83. doi: 10.1126/science.1245625. Epub 2013 Oct 31.
2
Sieve analysis in HIV-1 vaccine efficacy trials.HIV-1 疫苗功效试验中的筛检分析。
Curr Opin HIV AIDS. 2013 Sep;8(5):432-6. doi: 10.1097/COH.0b013e328362db2b.
3
Immune-correlates analysis of an HIV-1 vaccine efficacy trial.HIV-1 疫苗功效试验的免疫相关性分析。
加权 lambda 超弦在疫苗设计中的应用。
PLoS One. 2019 Feb 8;14(2):e0211714. doi: 10.1371/journal.pone.0211714. eCollection 2019.
4
Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site.HIV-1 包膜 CD4 结合位点抗体中和广度的精细表位特征。
JCI Insight. 2018 Mar 8;3(5):97018. doi: 10.1172/jci.insight.97018.
5
Selection of peptide mimics of HIV-1 epitope recognized by neutralizing antibody VRC01.选择可被中和抗体VRC01识别的HIV-1表位的肽模拟物。
PLoS One. 2015 Mar 18;10(3):e0120847. doi: 10.1371/journal.pone.0120847. eCollection 2015.
6
Could vaccination with AIDSVAX immunogens have resulted in antibody-dependent enhancement of HIV infection in human subjects?使用AIDSVAX免疫原进行疫苗接种会导致人类受试者体内HIV感染的抗体依赖性增强吗?
Hum Vaccin Immunother. 2014;10(10):3013-6. doi: 10.4161/21645515.2014.972148. Epub 2014 Nov 21.
7
Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes.针对HIV-1 gp120可变环表位的交叉亚型疫苗。
Vaccine. 2014 Sep 3;32(39):4916-24. doi: 10.1016/j.vaccine.2014.07.026. Epub 2014 Jul 18.
N Engl J Med. 2012 Apr 5;366(14):1275-86. doi: 10.1056/NEJMoa1113425.
4
Indirect detection of an epitope-specific response to HIV-1 gp120 immunization in human subjects.在人体中对 HIV-1 gp120 免疫的表位特异性反应的间接检测。
PLoS One. 2011;6(11):e27279. doi: 10.1371/journal.pone.0027279. Epub 2011 Nov 4.
5
Broad neutralization coverage of HIV by multiple highly potent antibodies.多种高效价抗体对 HIV 的广泛中和覆盖。
Nature. 2011 Sep 22;477(7365):466-70. doi: 10.1038/nature10373.
6
Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.V3 支架蛋白免疫原诱导的跨 HIV-1 中和抗体,继 gp120 DNA 初免之后。
J Virol. 2011 Oct;85(19):9887-98. doi: 10.1128/JVI.05086-11. Epub 2011 Jul 27.
7
Global trends in molecular epidemiology of HIV-1 during 2000-2007.2000-2007 年期间 HIV-1 分子流行病学的全球趋势。
AIDS. 2011 Mar 13;25(5):679-89. doi: 10.1097/QAD.0b013e328342ff93.
8
Quantitative assessment of masking of neutralization epitopes in HIV-1.HIV-1 中和表位掩蔽的定量评估。
Vaccine. 2011 Sep 9;29(39):6736-41. doi: 10.1016/j.vaccine.2010.12.052. Epub 2011 Jan 7.
9
Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopes.HIV 可变环中和表位的跨株保守性比较。
PLoS One. 2010 Dec 29;5(12):e15994. doi: 10.1371/journal.pone.0015994.
10
Conserved structural elements in the V3 crown of HIV-1 gp120.HIV-1 gp120 V3 冠部的保守结构元件。
Nat Struct Mol Biol. 2010 Aug;17(8):955-61. doi: 10.1038/nsmb.1861. Epub 2010 Jul 11.